Table 4 Main therapeutics used in our cohort, during follow-up. Results are presented into absolute values, and as a percentage of the overall cohort in parentheses. AAS, acetylsalicylic acid; ASCT, autologous stem cell transplant; IVIg, intravenous immunoglobulins; NSAI, nonsteroidal anti-inflammatory; PAH, pulmonary arterial hypertension
From: An updated overview of Juvenile systemic sclerosis in a French cohort
Immunosuppressors / modulators | 15 (83) |
|---|---|
Corticosteroids | 14 (78) |
Methotrexate | 10 (56) |
Mycophenolate | 8 (44) |
Cyclophosphamide | 1 (6) |
Hydroxychloroquine | 4 (22) |
Biologicals | 3 (17) |
Rituximab | 2 (11) |
Tocilizumab | 2 (11) |
IVIg | 3 (17) |
Vasodilators | 11 (61) |
Anticalcic | 10 (56) |
Bosentan | 1 (6) |
Iloprost | 2 (11) |
PAH treatment | 1 (6) |
Anti-fibrotic nintedanib | 1 (6) |
ASCT | 0 |
Organ transplant | 1 (6) |
AAS | 4 (22) |
NSAI | 2 (11) |
Proton pump inhibitors | 10 (56) |